Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE 1/2A STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF PF-07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS

X
Trial Profile

A PHASE 1/2A STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF PF-07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atirmociclib (Primary) ; Midazolam (Primary) ; Enzalutamide; Fulvestrant; Letrozole
  • Indications Adenocarcinoma; Advanced breast cancer; Colorectal cancer; HER2 negative breast cancer; HER2 positive breast cancer; Liposarcoma; Non-small cell lung cancer; Prostate cancer; Solid tumours
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Acronyms CDK4i
  • Sponsors Pfizer
  • Most Recent Events

    • 04 Jun 2024 Results assessing updated safety data for PF-07220060 + ET in pts with HR+/HER2- advanced/metastatic breast cancer (mBC), including extended follow-up data for pts in dose-finding cohorts (Parts 1B-C) and first disclosure of data for pts in dose-expansion cohorts (Parts 2B-C), presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
    • 04 Jun 2024 Updated safety data for PF-07220060 + ET in pts with HR+/HER2-advanced/metastatic breast cancer), including extended follow-up data for pts in dose-finding cohorts (Parts 1B-C) and first disclosure of data for pts in dose-expansion cohorts (Parts 2B-C), presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
    • 02 Apr 2024 Planned End Date changed from 19 Oct 2027 to 4 May 2028.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top